<DOC>
	<DOCNO>NCT00240552</DOCNO>
	<brief_summary>This open-label study enable HIV-infected adult limit treatment option receive fosamprenavir commercial supply available Switzerland .</brief_summary>
	<brief_title>Fosamprenavir Expanded Access</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>HIV1 infected subject . Subjects must belong one follow population : 1 . Subjects limit treatment option due viral resistance , interaction , tolerability issue antiretroviral drug . 2 . Subjects already receive amprenavir ( AgeneraseÂ® ) 3 . Subjects daily dose antiretroviral therapy indicate , include , daily dose fosamprenavir/ritonavir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>protease inhibitor</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>amprenavir</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>GW433908</keyword>
	<keyword>HIV</keyword>
	<keyword>pro drug</keyword>
</DOC>